TOR Pathway

Fuatilia
Scientist examining extended-lifespan yeast cells under microscope with rapalink-1 cancer drug vial, illustrating anti-aging breakthrough.
Picha iliyoundwa na AI

Next-generation cancer drug shows anti-aging effects in yeast

Imeripotiwa na AI Picha iliyoundwa na AI Imethibitishwa ukweli

Researchers at Queen Mary University of London have found that rapalink-1, an experimental TOR inhibitor being investigated for cancer therapy, extends the lifespan of fission yeast. The study also uncovered a role for agmatinases in regulating the TOR pathway through a metabolic feedback loop, suggesting potential links between diet, gut microbes, and aging.

Tovuti hii inatumia vidakuzi

Tunatumia vidakuzi kwa uchambuzi ili kuboresha tovuti yetu. Soma sera ya faragha yetu kwa maelezo zaidi.
Kataa